
    
      To assess the single dose plasma pharmacokinetics (PK), safety, and tolerability of celecoxib
      in healthy subjects with CYP2C9 extensive metabolizer (EM) genotype when administered alone
      and following multiple daily doses of AKB-6548.
    
  